Renal Cell Carcinoma and Interferon at the Millennium

REFERENCES

• Motzer R. J., Bander N. H., Nanus D. M. Renal-Cell Carcinoma. N. Engl. J. Med. 1996; 335: 865–875
   PubMed Web of Science ®Google Scholar
• Greenlee R. T., Hill-Harmon M. B., Murray T., et al. Cancer Statistics, 2001. CA Cancer J. Clin. 2001; 51: 15–36
   PubMed Web of Science ®Google Scholar
• Wirth M. P. Immunotherapy for Metastatic Renal Cell Carcinoma. Urol. Clin. North Am. 1993; 20: 283–295
   PubMed Web of Science ®Google Scholar
• Bukowski R. M. Immunotherapy in Renal Cell Carcinoma. Oncology 1999; 13: 801–810
   PubMed Web of Science ®Google Scholar
• Kontsek P., Kontsekova E. Forty Years of Interferon. Acta Virol. 1997; 41: 349–353
   PubMed Web of Science ®Google Scholar
• Wan Y. J., Orrison B. M., Lieberman R., et al. Induction of Major Histocompatibility Class I Antigens by Interferons in Undifferentiated F9 Cells. J. Cell. Physiol. 1987; 130: 276–283
   PubMed Web of Science ®Google Scholar
• Van Vliet E., Molenaar J. L., Tuk C. W., et al. Recombinant Gamma Interferon Induces Class II Major Histocompatibility Complex Antigens on Insulinoma Cells. Tissue Antigens 1987; 29: 195–200
   PubMed Web of Science ®Google Scholar
• Gajewski T. F., Fitch F. W. Anti-Proliferative Effect of IFN-Gamma in Immune Regulation. I. IFN-Gamma Inhibits the Proliferation of Th2 But Not Th1 Murine Helper T Lymphocyte Clones. J. Immunol. 1988; 140: 4245–4252
   PubMed Web of Science ®Google Scholar
• Fernandez-Botran R., Sanders V. M., Mosmann T. R., et al. Lymphokine-Mediated Regulation of the Proliferative Response of Clones of T Helper 1 and T Helper 2 Cells. J. Exp. Med. 1988; 168: 543–558
   PubMed Web of Science ®Google Scholar
• Leaman D. W. Mechanisms of Interferon Action. Prog. Mol. Subcell. Biol. 1998; 20: 101–142
   PubMedGoogle Scholar
• Stark G. R., Kerr I. M., Williams B. R., et al. How Cells Respond to Interferons. Annu. Rev. Biochem. 1998; 67: 227–264
   PubMed Web of Science ®Google Scholar
• Vanden C. Broecke, Pfeffer L. M. Characterization of Interferon-Alpha Binding Sites on Human Cell Lines. J. Interferon Res. 1988; 8: 803–811
   PubMedGoogle Scholar
• Platanias L. C., Pfeffer L. M., Cruciani R., et al. Characterization of the Alpha Subunit of the IFN-Alpha Receptor. Evidence of N- and O-Linked Glycosylation and Association with Other Surface Proteins. J. Immunol. 1993; 150: 3382–3388
   PubMed Web of Science ®Google Scholar
• Uze G., Lutfalla G., Gresser I. Genetic Transfer of a Functional Human Interferon Alpha Receptor into Mouse Cells: Cloning and Expression of Its cDNA. Cell 1990; 60: 225–234
   PubMed Web of Science ®Google Scholar
• Domanski P., Witte M., Kellum M., et al. Cloning and Expression of a Long Form of the Beta Subunit of the Interferon Alpha Beta Receptor That Is Required for Signaling. J. Biol. Chem. 1995; 270: 21606–21611
   PubMed Web of Science ®Google Scholar
• Lutfalla G., Holland S. J., Cinato E., et al. Mutant U5A Cells Are Complemented by an Interferon-Alpha Beta Receptor Subunit Generated by Alternative Processing of a New Member of a Cytokine Receptor Gene Cluster. EMBO J. 1995; 14: 5100–5108
   PubMed Web of Science ®Google Scholar
• Novick D., Cohen B., Rubinstein M. The Human Interferon Alpha/Beta Receptor: Characterization and Molecular Cloning. Cell 1994; 77: 391–400
   PubMed Web of Science ®Google Scholar
• Colamonici O. R., Porterfield B., Domanski P., et al. Complementation of the Interferon Alpha Response in Resistant Cells by Expression of the Cloned Subunit of the Interferon Alpha Receptor. A Central Role of This Subunit in Interferon Alpha Signaling. J. Biol. Chem. 1994; 269: 9598–9602
   PubMed Web of Science ®Google Scholar
• Hemmi S., Bohni R., Stark G., et al. A Novel Member of the Interferon Receptor Family Complements Functionality of the Murine Interferon Gamma Receptor in Human Cells. Cell 1994; 76: 803–810
   PubMed Web of Science ®Google Scholar
• Aguet M., Dembic Z., Merlin G. Molecular Cloning and Expression of the Human Interferon-Gamma Receptor. Cell 1988; 55: 273–280
   PubMed Web of Science ®Google Scholar
• Soh J., Donnelly R. J., Kotenko S., et al. Identification and Sequence of an Accessory Factor Required for Activation of the Human Interferon Gamma Receptor. Cell 1994; 76: 793–802
   PubMed Web of Science ®Google Scholar
• Bazan J. F. Shared Architecture of Hormone Binding Domains in Type I and II Interferon Receptors. Cell 1990; 61: 753–754
   PubMed Web of Science ®Google Scholar
• Muller M., Briscoe J., Laxton C., et al. The Protein Tyrosine Kinase JAK1 Complements Defects in Interferon-Alpha/Beta and -Gamma Signal Transduction. Nature 1993; 366: 129–135
   PubMed Web of Science ®Google Scholar
• Velazquez L., Fellous M., Stark G. R., et al. A Protein Tyrosine Kinase in the Interferon Alpha-Beta Signaling Pathway. Cell 1992; 70: 313–322
   PubMed Web of Science ®Google Scholar
• Schindler C., Shuai K., Prezioso V. R., et al. Interferon-Dependent Tyrosine Phosphorylation of a Latent Cytoplasmic Transcription Factor. Science 1992; 257: 809–813
   PubMed Web of Science ®Google Scholar
• Fu X. Y. A Transcription Factor with SH2 and SH3 Domains Is Directly Activated by an Interferon Alpha-Induced Cytoplasmic Protein Tyrosine Kinase(s). Cell 1992; 70: 323–335
   PubMed Web of Science ®Google Scholar
• Ihle J. N., Witthuhn B. A., Quelle F. W., et al. Signaling by the Cytokine Receptor Superfamily: JAKs and STATs. Trends Biochem. Sci. 1994; 19: 222–227
   PubMed Web of Science ®Google Scholar
• Colamonici O. R., Uyttendaele H., Domanski P., et al. p135tyk2, an Interferon-Alpha-Activated Tyrosine Kinase, Is Physically Associated with an Interferon-Alpha Receptor. J. Biol. Chem. 1994; 269: 3518–3522
   PubMed Web of Science ®Google Scholar
• Sakatsume M., Igarashi K., Winestock K. D., et al. The Jak Kinases Differentially Associate with the Alpha and Beta (Accessory Factor) Chains of the Interferon Gamma Receptor to Form a Functional Receptor Unit Capable of Activating STAT Transcription Factors. J. Biol. Chem. 1995; 270: 17528–17534
   PubMed Web of Science ®Google Scholar
• Kaplan D. H., Greenlund A. C., Tanner J. W., et al. Identification of an Interferon-Gamma Receptor Alpha Chain Sequence Required for JAK-1 Binding. J. Biol. Chem. 1996; 271: 9–12
   PubMed Web of Science ®Google Scholar
• Greenlund A. C., Farrar M. A., Viviano B. L., et al. Ligand-Induced IFN Gamma Receptor Tyrosine Phosphorylation Couples the Receptor to Its Signal Transduction System (p91). EMBO J. 1994; 13: 1591–1600
   PubMed Web of Science ®Google Scholar
• Yang C. H., Shi W., Basu L., et al. Direct Association of STAT3 with the IFNAR-1 Chain of the Human Type I Interferon Receptor. J. Biol. Chem. 1996; 271: 8057–8061
   PubMed Web of Science ®Google Scholar
• Friedman R. L., Stark G. R. Alpha-Interferon-Induced Transcription of Hla and Metallothionein Genes Containing Homologous Upstream Sequences. Nature 1985; 314: 637–639
   PubMed Web of Science ®Google Scholar
• Reich N., Evans B., Levy D., et al. Interferon-Induced Transcription of a Gene Encoding a 15-kDa Protein Depends on an Upstream Enhancer Element. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 6394–6398
   PubMed Web of Science ®Google Scholar
• Campbell G. S., Meyer D. J., Raz R., et al. Activation of Acute Phase Response Factor (APRF)/Stat3 Transcription Factor by Growth Hormone. J. Biol. Chem. 1995; 270: 3974–3979
   PubMedGoogle Scholar
• Boulton T. G., Zhong Z., Wen Z., et al. STAT3 Activation by Cytokines Utilizing gp130 and Related Transducers Involves a Secondary Modification Requiring an H7-Sensitive Kinase. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 6915–6919
   PubMed Web of Science ®Google Scholar
• Zhong Z., Wen Z., Darnell J. E., Jr. STAT3 and STAT4: Members of the Family of Signal Transducers and Activators of Transcription. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 4806–4810
   PubMed Web of Science ®Google Scholar
• Akira S., Nishio Y., Inoue M., et al. Molecular Cloning of APRF, a Novel IFN-Stimulated Gene Factor 3 p91-Related Transcription Factor Involved in the gp130-Mediated Signaling Pathway. Cell 1994; 77: 63–71
   PubMed Web of Science ®Google Scholar
• Wen Z., Zhong Z., Darnell J. E., Jr. Maximal Activation of Transcription by STAT1 and STAT3 Requires Both Tyrosine and Serine Phosphorylation. Cell 1995; 82: 241–250
   PubMed Web of Science ®Google Scholar
• Takeda K., Noguchi K., Shi W., et al. Targeted Disruption of the Mouse Stat3 Gene Leads to Early Embryonic Lethality. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 3801–3804
   PubMed Web of Science ®Google Scholar
• Takeda K., Kaisho T., Yoshida N., et al. STAT3 Activation Is Responsible for IL-6-Dependent T Cell Proliferation Through Preventing Apoptosis: Generation and Characterization of T Cell-Specific STAT3-Deficient Mice. J. Immunol. 1998; 161: 4652–4660
   PubMed Web of Science ®Google Scholar
• Zushi S., Shinomura Y., Kiyohara T., et al. STAT3 Mediates the Survival Signal in Oncogenic Ras-Transfected Intestinal Epithelial Cells. Int. J. Cancer 1998; 78: 326–330
   PubMed Web of Science ®Google Scholar
• Yang C. H., Murti A., Pfeffer L. M. STAT3 Complements Defects in an Interferon-Resistant Cell Line: Evidence for an Essential Role for STAT3 in Interferon Signaling and Biological Activities. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 5568–5572
   PubMed Web of Science ®Google Scholar
• Pfeffer L. M., Mullersman J. E., Pfeffer S. R., et al. STAT3 as an Adapter to Couple Phosphatidylinositol 3–Kinase to the IFNAR1 Chain of the Type I Interferon Receptor. Science 1997; 276: 1418–1420
   PubMed Web of Science ®Google Scholar
• Burgering B. M., Coffer P. J. Protein Kinase B (c-Akt) in Phosphatidylinositol-3-OH Kinase Signal Transduction. Nature 1995; 376: 599–602
   PubMed Web of Science ®Google Scholar
• Franke T. F., Yang S. I., Chan T. O., et al. The Protein Kinase Encoded by the Akt Proto-Oncogene Is a Target of the PDGF-Activated Phosphatidylinositol 3-Kinase. Cell 1995; 81: 727–736
   PubMed Web of Science ®Google Scholar
• Darnell J. E., Jr., Kerr I. M., Stark G. R. Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins. Science 1994; 264: 1415–1421
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Swanson D. A., Trindade A., et al. Renal Cell Carcinoma: Antitumor Effects of Leukocyte Interferon. Cancer Res. 1983; 43: 940–947
   PubMed Web of Science ®Google Scholar
• De Kernion J. B., Sarna G., Figlin R., et al. The Treatment of Renal Cell Carinocma with Human Leukocyte Alpha-Interferon. J. Urol. 1983; 130: 1063–1066
   PubMed Web of Science ®Google Scholar
• Choudhury M., Efros M., Mittelman A. Interferons and Interleukins in Metastatic Renal Cell Carcinoma. Urology 1993; 41: 67–72
   PubMed Web of Science ®Google Scholar
• Haas G. P., Hillman G. G., Redman B. G., et al. Immunotherapy of Renal Cell Carcinoma. CA Cancer J. Clin. 1993; 43: 177–187
   PubMed Web of Science ®Google Scholar
• Gilewski T., Vogelzang N. J. Cost-Effectiveness and Reimbursement Issues in Renal Cell Carcinoma. Semin. Oncol. 1989; 16: 20–26
   PubMed Web of Science ®Google Scholar
• Krown S. E. Interferon in 1987: The Half Full Glass. J. Cancer. Res. Clin. Oncol. 1987; 113: 503–506
   PubMed Web of Science ®Google Scholar
• Horoszewicz J. S., Murphy G. P. An Assessment of the Current Use of Human Interferons in Therapy of Urological Cancers. J. Urol. 1989; 142: 1173–1180
   PubMed Web of Science ®Google Scholar
• Goey S. H., Verweij J., Stoter G. Immunotherapy of Metastatic Renal Cell Cancer. Ann. Oncol. 1996; 7: 887–900
   PubMed Web of Science ®Google Scholar
• Prummer O. Interferon-Alpha Antibodies in Patients with Renal Cell Carcinoma Treated with Recombinant Interferon-Alpha-2A in an Adjuvant Multicenter Trial. The Delta-P Study Group. Cancer 1993; 71: 1828–1834
   PubMed Web of Science ®Google Scholar
• Kriegmair M., Oberneder R., Hofstetter A. Interferon Alfa and Vinblastine Versus Medroxyprogesterone Acetate in the Treatment of Metastatic Renal Cell Carcinoma. Urology 1995; 45: 758–762
   PubMed Web of Science ®Google Scholar
• Pyrhönen S., Salminen E., Ruutu M., et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients with Advanced Renal Cell Cancer. J. Clin. Oncol. 1999; 17: 2859–2867
   PubMed Web of Science ®Google Scholar
• Interferon-Alpha and Survival in Metastatic Renal Carcinoma: Early Results of a Randomised Controlled Trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353: 14–17
   PubMed Web of Science ®Google Scholar
• Cameron R. B., McIntosh J. K., Rosenberg S. A. Synergistic Antitumor Effects of Combination Immunotherapy with Recombinant Interleukin-2 and a Recombinant Hybrid Alpha-Interferon in the Treatment of Established Murine Hepatic Metastases. Cancer Res. 1988; 48: 5810–5817
   PubMed Web of Science ®Google Scholar
• Chikkala N. F., Lewis I., Ulchaker J., et al. Interactive Effects of Alpha-Interferon A/D and Interleukin 2 on Murine Lymphokine-Activated Killer Activity: Analysis at the Effector and Precursor Level. Cancer Res. 1990; 50: 1176–1182
   PubMed Web of Science ®Google Scholar
• Bukowski R. M. Natural History and Therapy of Metastatic Renal Cell Carcinoma: The Role of Interleukin-2. Cancer 1997; 80: 1198–1220
   PubMed Web of Science ®Google Scholar
• Henriksson R., Nilsson S., Colleen S., et al. Survival in Renal Cell Carcinoma—a Randomized Evaluation of Tamoxifen vs Interleukin 2, Alpha-Interferon (Leucocyte) and Tamoxifen. Br. J. Cancer 1998; 77: 1311–1317
   PubMed Web of Science ®Google Scholar
• Negrier S., Escudier B., Lasset C., et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma. Groupe Français d’Immunothérapie. N. Engl. J. Med. 1998; 338: 1272–1278
   PubMed Web of Science ®Google Scholar
• Elias L., Sandoval J. M. Inteferon Effects upon Fluorouracil Metabolism by HL-60 Cells. Biochem. Biophys. Res. Commun. 1989; 163: 867–874
   PubMed Web of Science ®Google Scholar
• Kirchner H., Buer J., Probst-Kepper M. Risk and Long-Term Outcome in Metastatic Renal Cell Carcinoma Patients Receiving Subcutaneous Interleukin-2, Subcutaneous Interferon-Alfa 2A and Intravenous Fluorouracil. Proc. Am. Soc. Clin. Oncol. 1998; 17: 310a
   Google Scholar
• Négrier S., Caty A., Lesimple T., et al. Treatment of Patients with Metastatic Renal Carcinoma with a Combination of Subcutaneous Interleukin-2 and Interferon Alfa with or Without Fluorouracil. J. Clin. Oncol. 2000; 18: 4009–4015
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Schwartz L., Law T. M., et al. Inteferon Alfa-2a and 13-cis-Retinoic Acid in Renal Cell Carcinoma: Antitumor Activity in a Phase II Trial and Interactions In Vitro. J. Clin. Oncol. 1995; 13: 1950–1957
   PubMed Web of Science ®Google Scholar
• Berg W. J., Schwartz L. H., Amsterdam A., et al. A Phase II Study of 13-cis-Retinoic Acid in Patients with Advanced Renal Cell Carcinoma. Invest. New Drugs 1997; 15: 353–355
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Murphy B. A., Bacik J., et al. Phase III Trial of Interferon Alfa-2a with or Without 13-cis-Retinoic Acid for Patients with Advanced Renal Cell Carcinoma. Proc. Am. Soc. Clin. Oncol. 2000; 18: 2972–2980
   PubMed Web of Science ®Google Scholar
• Buer J., Probst M., Ganser A., et al. Response to 13-cis-Retinoic Acid Plus Interferon Alfa-2a in Two Patients with Therapy-Refractory Advanced Renal Cell Carcinoma. J. Clin. Oncol. 1995; 13: 2679–2680
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Kirchner H., Duensing S., et al. Biochemotherapy of Advanced Metastatic Renal-Cell Carcinoma: Results of the Combination of Interleukin-2, Alpha-Interferon, 5-Fluorouracil, Vinblastine, and 13-cis-Retinoic Acid. World J. Urol. 1995; 13: 174–177
   PubMed Web of Science ®Google Scholar
• Bukowski R. M., Novick A. C. Clinical Practice Guidelines: Renal Cell Carcinoma. Cleve. Clin. J. Med. 1997; 64: SI4–SI44
   Google Scholar
• Aulitzky W., Gastl G., Aulitzky W. E., et al. Successful Treatment of Metastatic Renal Cell Carcinoma with a Biologically Active Dose of Recombinant Interferon-Gamma. J. Clin. Oncol. 1989; 7: 1875–1884
   PubMed Web of Science ®Google Scholar
• Small E. J., Weiss G. R., Malik U. K., et al. The Treatment of Metastatic Renal cell Carcinoma Patients with Recombinant Human Gamma Interferon. Cancer J. Sci. Am. 1998; 4: 162–167
   PubMed Web of Science ®Google Scholar
• Gleave M. E., Elhilali M., Fradet Y., et al. Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. Canadian Urologic Oncology Group. N. Engl. J. Med. 1998; 338: 1265–1271
   PubMed Web of Science ®Google Scholar
• Pizzocaro G., Piva L., Colavita M., et al. Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized Study. J. Clin. Oncol. 2001; 19: 425–431
   PubMed Web of Science ®Google Scholar
• Basting R., Corvin S., Handel D., et al. Adjuvant Immunotherapy in Renal Cell Carcinoma—Comparison of Interferon Alpha Treatment with an Untreated Control. Anticancer Res. 1999; 19: 1545–1548
   PubMed Web of Science ®Google Scholar
• Maldazys J. D., de Kernion J. B. Prognostic Factors in Metastatic Renal Carcinoma. J. Urol. 1986; 136: 376–379
   PubMed Web of Science ®Google Scholar
• Figlin R. A., Abi-Aad A. S., Belldegrun A., et al. The Role of Interferon and Interleukin-2 in the Immunotherapeutic Approach to Renal Cell Carcinoma. Semin. Oncol. 1991; 18: 102–107
   PubMed Web of Science ®Google Scholar
• Minasian L. M., Motzer R. J., Gluck L., et al. Interferon Alfa-2a in Advanced Renal Cell Carcinoma: Treatment Results and Survival in 159 Patients with Long-Term Follow-Up. J. Clin. Oncol. 1993; 11: 1368–1375
   PubMed Web of Science ®Google Scholar
• Mani S., Todd M. B., Katz K., et al. Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers. J. Urol. 1995; 154: 35–40
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Mazumdar M., Bacik J., et al. Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma. J. Clin. Oncol. 1999; 17: 2530–2540
   PubMed Web of Science ®Google Scholar
• Johnson D. E., Kaesler K. E., Samuels M. L. Is Nephrectomy Justified in Patients with Metastatic Renal Carcinoma?. J. Urol. 1975; 114: 27–29
   PubMed Web of Science ®Google Scholar
• Flanigan R. C., Blumenstein B. A., Salmon S., et al. Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949. Proc. Am. Urol. Assoc. 2000; 163: 154
   Google Scholar
• Flanigan R. C., Blumenstein B. A., Salmon S., et al. Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949. Proc. Am. Soc. Clin. Oncol. 2000; 19: 2a
   Google Scholar
• Figlin R. A. Renal Cell Carcinoma: Management of Advanced Disease. J. Urol. 1999; 161: 381–386
   PubMed Web of Science ®Google Scholar
• Wolchok J. D., Motzer R. J. Management of Renal Cell Carcinoma. Oncology 2000; 14: 29–34
   PubMed Web of Science ®Google Scholar
• Oosterwijk E., Debruyne F. M., Schalken J. A. The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma. Semin. Oncol. 1995; 22: 34–41
   PubMed Web of Science ®Google Scholar
• Divgi C. R., Bander N. H., Scott A. M., et al. Phase I/II Radioimmunotherapy Trial with Iodine-131-Labeled Monoclonal Antibody G250 in Metastatic Renal Cell Carcinoma. Clin. Cancer Res. 1998; 4: 2729–2739
   PubMed Web of Science ®Google Scholar
• Steffens M. G., Boerman O. C., Oyen W. J., et al. Intratumoral Distribution of Two Consecutive Injections of Chimeric Antibody G250 in Primary Renal Cell Carcinoma: Implications for Fractionated Dose Radioimmunotherapy. Cancer Res. 1999; 59: 1615–1619
   PubMed Web of Science ®Google Scholar
• Van Dijk J., Uemura H., Beniers A. J., et al. Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, in Mice with Renal-Cell Carcinoma Xenografts. Int. J. Cancer 1994; 56: 262
   PubMed Web of Science ®Google Scholar